Status:
TERMINATED
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Escherichia Coli Infections
Staphylococcus Aureus
Eligibility:
All Genders
8-75 years
Brief Summary
Our previous studies delineate a novel pathway of immune activation in animals that the investigators have named Anti-Virulence Immunity (AVI). Using a mice model of bacteremia, the investigators have...
Eligibility Criteria
Inclusion
- Patient with S. aureus or E. coli bacteriostatic bacteremia defined by at least one positive blood culture bottle
- Patient requiring a blood test as part of his bacteremia
- not subject to a judicial protection measure
- Signature of the non-opposition of consent (for minor patients signed by one of the parents or the representative of the parental authority)
- Affiliation to social security
Exclusion
- Immunocompromised patient defined by:
- current immunosuppressive therapies: corticosteroids, chemotherapy, biotherapy
- solid organ transplant patient or hematopoietic stem cell transplant
- chemotherapy-induced neutropenia
- Congenital immune deficiency
- bacteremia related to a peripheral or central catheter
- Urinary obstruction not lifted within the first 24 hours of management
- Intra-abdominal infection collected undrained in the first 24 hours of management
- primary infectious focus represented by mechanically ventilated pneumonia
- Pregnant or lactating woman
Key Trial Info
Start Date :
June 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03869593
Start Date
June 3 2019
End Date
September 1 2023
Last Update
July 22 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHG d'Antibes
Antibes, France
2
CH Pierre Nouveau
Cannes, France
3
CHU de Lenval
Nice, France